Maintenance treatments containing the immunomodulatory therapy Revlimid (lenalidomide) are the best option for patients with multiple myeloma, according to a recent meta-analysis. The study, “…
News
Amgen is seeking to expand the approval of its proteasome inhibitor Kyprolis (carfilzomib) in the U.S. to include once-weekly dosing combined with dexamethasone for…
The U.S. Food and Drug Administration granted priority review to Bristol-Myers Squibb’s supplemental Biologics License Application (sBLA) for Empliciti (elotuzumab) combined with Pomalyst (pomalidomide) and…
Adding BioLineRx‘s BL-8040 to standard treatment greatly improves the mobilization of blood stem cells to be collected for stem cell transplants in patients…
SRF231, an experimental anti-CD47 immunotherapy candidate developed by Surface Oncology, was granted orphan drug status by the U.S. Food and Drug Administration for…
The U.S. Food and Drug Administration has granted orphan drug status to SRF231 to treat multiple myeloma, according to Surface Oncology, which is developing…
Expanded use of Darzalex (daratumumab) in combination with standard therapy for treating adult patients with newly-diagnosed multiple myeloma, and who are not candidates for stem cell…
Inserting data from genetically similar patients into a machine-learning algorithm may help predict which multiple myeloma patients will benefit from Velcade (bortezomib) or Revlimid (lenalidomide)…
Urine tests may be better than serum tests to diagnose multiple myeloma or its precursor conditions, because they can spot cases that…
Karyopharm Therapeutics is seeking accelerated approval for its investigational therapy selinexor in the United States as a treatment for heavily treated multiple myeloma…
